Perspective Therapeutics (NYSEAMERICAN:CATX) Shares Up 12.3% – Here’s What Happened

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) shot up 12.3% during trading on Thursday . The stock traded as high as $5.66 and last traded at $5.65. 3,831,322 shares were traded during trading, a decline of 46% from the average session volume of 7,128,467 shares. The stock had previously closed at $5.03.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on CATX shares. Wedbush reissued an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, November 11th. B. Riley Financial lowered their price target on Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Finally, UBS Group restated a “buy” rating and set a $7.00 price target (down from $18.00) on shares of Perspective Therapeutics in a research report on Friday, November 21st. Four equities research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $11.50.

Perspective Therapeutics Stock Performance

The business’s fifty day moving average is $3.42 and its 200-day moving average is $3.23. The company has a quick ratio of 8.66, a current ratio of 8.66 and a debt-to-equity ratio of 0.01.

Institutional Investors Weigh In On Perspective Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CATX. Russell Investments Group Ltd. lifted its stake in Perspective Therapeutics by 184.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after purchasing an additional 5,475 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Perspective Therapeutics in the 3rd quarter valued at about $46,000. Ground Swell Capital LLC bought a new stake in Perspective Therapeutics during the second quarter worth approximately $56,000. Los Angeles Capital Management LLC purchased a new stake in Perspective Therapeutics during the second quarter valued at approximately $61,000. Finally, Mercer Global Advisors Inc. ADV lifted its stake in shares of Perspective Therapeutics by 81.8% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 29,275 shares of the company’s stock valued at $100,000 after purchasing an additional 13,168 shares during the last quarter. Institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.